Mustafa Al-Dulaimi, BS, (mustafa_al-dulaimi@dfci.harvard.edu) works on investigating the impact of different combinations of RTKi treatments with the goal of overcoming and preventing acquired resistance to EGFR-targeted therapies in EGFR-mutant NSCLC. He also works on identifying targeted therapy options for mesotheliomas by researching potential therapeutic vulnerabilities.
Lishu Liao, BS, (lishu_liao@dfci.harvard.edu) mainly works on EGFR-mutant NSCLC cell lines with the focus of finding targetable vulnerabilities for EGFR-TKI resistant cells based on genes/pathways involved in DNA damage repair and cell cycle regulation. She is also responsible for establishing in vitro 2D & 3D cell line models of NSCLC from both PDX and patient pleural effusion samples.
Joe Kulesza, BS, (joseph_kulesza@dfci.harvard.edu) work involves understanding how non-small cell lung cancers develop resistance to targeted therapy. His current projects focus on the nuclear transcription factor AP-1 and the chromatin remodeling complex BAF.
Felix Gottlieb, BS, (felix_gottlieb@dfci.harvard.edu) works on identifying patterns of MET dysregulation as de novo oncogenic drivers in NSCLC. He also investigates MET dysregulation in the context of other oncogene-driven lung tumors, such as EGFR and KRAS, as well as novel targeted therapies for overcoming these resistance mechanisms.
William Godfrey, MSc, (william_godfrey@dfci.harvard.edu) is a research technician working with Sean Lenahan to understand YAP-mediated signaling pathways in drug-resistant persister cells that arise after treatment with EGFR inhibitors.